JP2008520736A5 - - Google Patents

Download PDF

Info

Publication number
JP2008520736A5
JP2008520736A5 JP2007543431A JP2007543431A JP2008520736A5 JP 2008520736 A5 JP2008520736 A5 JP 2008520736A5 JP 2007543431 A JP2007543431 A JP 2007543431A JP 2007543431 A JP2007543431 A JP 2007543431A JP 2008520736 A5 JP2008520736 A5 JP 2008520736A5
Authority
JP
Japan
Prior art keywords
composition
amantadine
memantine
use according
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520736A (ja
Filing date
Publication date
Priority claimed from US11/048,002 external-priority patent/US20050245617A1/en
Priority claimed from US11/058,118 external-priority patent/US20050209218A1/en
Priority claimed from US11/058,141 external-priority patent/US20050245460A1/en
Application filed filed Critical
Priority claimed from PCT/US2005/042424 external-priority patent/WO2006058059A2/en
Publication of JP2008520736A publication Critical patent/JP2008520736A/ja
Publication of JP2008520736A5 publication Critical patent/JP2008520736A5/ja
Pending legal-status Critical Current

Links

JP2007543431A 2004-11-23 2005-11-22 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法 Pending JP2008520736A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US63088504P 2004-11-23 2004-11-23
US63536504P 2004-12-10 2004-12-10
US63578604P 2004-12-13 2004-12-13
US11/048,002 US20050245617A1 (en) 2004-01-29 2005-01-31 Methods and compositions for the treatment of CNS-related conditions
US11/058,118 US20050209218A1 (en) 2004-02-13 2005-02-14 Methods and compositions for the treatment of psychiatric conditions
US11/058,141 US20050245460A1 (en) 2004-02-13 2005-02-14 Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
US70185705P 2005-07-22 2005-07-22
PCT/US2005/042424 WO2006058059A2 (en) 2004-11-23 2005-11-22 Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009073540A Division JP2009173669A (ja) 2004-11-23 2009-03-25 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法

Publications (2)

Publication Number Publication Date
JP2008520736A JP2008520736A (ja) 2008-06-19
JP2008520736A5 true JP2008520736A5 (https=) 2009-01-15

Family

ID=36088318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007543431A Pending JP2008520736A (ja) 2004-11-23 2005-11-22 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法
JP2009073540A Pending JP2009173669A (ja) 2004-11-23 2009-03-25 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009073540A Pending JP2009173669A (ja) 2004-11-23 2009-03-25 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法

Country Status (12)

Country Link
EP (2) EP1827385B1 (https=)
JP (2) JP2008520736A (https=)
KR (1) KR101301429B1 (https=)
AU (1) AU2005309601A1 (https=)
BR (1) BRPI0518483A2 (https=)
CA (1) CA2588295C (https=)
DE (1) DE05852057T1 (https=)
IL (1) IL183384A0 (https=)
MX (1) MX2007006120A (https=)
RU (1) RU2404750C2 (https=)
SG (1) SG157415A1 (https=)
WO (1) WO2006058059A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
JP2007246507A (ja) * 2006-02-15 2007-09-27 Kracie Seiyaku Kk 疲労の予防・治療組成物及び予防・治療方法
WO2008005036A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2236160A3 (en) * 2009-03-31 2011-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release dimebolin formulations
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
EP2585049A1 (en) * 2010-06-24 2013-05-01 Merz Pharma GmbH & Co. KGaA Neramexane multiple unit dosage form
US20140004189A1 (en) * 2011-01-25 2014-01-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2014174564A1 (ja) * 2013-04-22 2014-10-30 祐徳薬品工業株式会社 メマンチン含有経皮吸収型貼付製剤
WO2014199455A1 (ja) * 2013-06-12 2014-12-18 祐徳薬品工業株式会社 メマンチン経皮吸収型貼付製剤
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
AU2018320946B2 (en) 2017-08-24 2024-05-02 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
IT201800011125A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
IT202000011050A1 (it) 2020-05-14 2021-11-14 Mogon Pharmaceuticals Sagl Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi
IT202000011053A1 (it) 2020-05-14 2021-11-14 Int Health Science S R L Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di alimenti, integratori alimentari, nutraceutici, dispositivi medici
WO2022025785A1 (ru) 2020-07-29 2022-02-03 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Фармацевтическая композиция, включающая мемантин и цитиколин

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4284444A (en) 1977-08-01 1981-08-18 Herculite Protective Fabrics Corporation Activated polymer materials and process for making same
US4346112A (en) 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
ATE59302T1 (de) 1984-07-24 1991-01-15 Key Pharma Klebende schicht zur transdermalen freigabe.
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
ES2059602T3 (es) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO1998007447A1 (en) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5919826A (en) 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP0946145B1 (en) 1996-12-20 2008-09-03 McNeil-PPC, Inc. Antitussive drugs delivered by ion exchange resins
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
PT1140012E (pt) 1998-12-17 2004-05-31 Alza Corp Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas
CN1736502A (zh) 1999-03-03 2006-02-22 奥普蒂诺斯公司 鼻传送装置
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
WO2001019901A2 (en) 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
KR100889069B1 (ko) * 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
PT1509232E (pt) * 2002-05-31 2009-01-07 Lundbeck & Co As H Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
US6662845B1 (en) 2002-06-19 2003-12-16 Newell Operating Company Roman shade with separated backing sheet
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
DE60317225T2 (de) 2002-06-26 2008-05-29 Intarcia Therapeutics, Inc., Emeryville Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
TW200418446A (en) 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
JP2004161636A (ja) * 2002-11-11 2004-06-10 Takeda Chem Ind Ltd 軽度認知障害または注意欠陥多動性障害治療剤
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
AR043467A1 (es) * 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
US20050065219A1 (en) * 2003-03-27 2005-03-24 Lipton Stuart A. Treatment of demyelinating conditions
MXPA05012810A (es) * 2003-06-16 2006-02-13 Allergan Inc Formas de dosis oral de memantina.
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
WO2005079773A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
EP1898890A1 (en) * 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation

Similar Documents

Publication Publication Date Title
JP2008520736A5 (https=)
KR102726728B1 (ko) 과다 졸림증을 치료하기 위한 방법 및 조성물
US7094427B2 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
CN101528203B (zh) 用于基于择时治疗理论治疗心血管疾病的联合制剂
JP6043785B2 (ja) 注意欠陥障害の処置のための方法および組成物
JP7534354B2 (ja) 朝の無動状態を治療するための拍動性薬物送達系
JP6038203B2 (ja) アマンタジン組成物および使用方法
US20090253728A1 (en) Methods and Compositions for Treating Nociceptive Pain
CA2628200A1 (en) Solid pharmaceutical compositions containing pregabalin
JP2005507400A5 (https=)
JP2011504491A (ja) プレガバリンの制御放出医薬組成物
KR101156054B1 (ko) 안정한 에페리손 함유 서방성 의약조성물
DE05852057T1 (de) Zusammensetzung aus einer beschichtung oder matrix mit verzögerter freisetzung und einem nmda-rezeptorantagonisten sowie verfahren zur verabreichung eines solchen nmda-rezeptorantagonisten an ein subjekt
JP2017532363A5 (https=)
JP2013512919A5 (https=)
US20030224045A1 (en) Combination immediate release sustained release levodopa/carbidopa dosage forms
CN107920987A (zh) 控制延缓释放普瑞巴林
JP2005528430A5 (https=)
KR20110005876A (ko) 다중 미립자를 함유하고 이중 방출 프로파일을 갖는 고체 경구용 제형
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
JP2023521664A (ja) ジバルプロエクスナトリウムとともにγ－ヒドロキシ酪酸塩組成物を投与する方法
TWI344840B (en) Modafinil modified release pharmaceutical compositions
KR20180108814A (ko) 다이메틸 퓨마레이트를 포함하는 약제학적 비드 제형
AU2018320946A1 (en) Amantadine compositions, preparations thereof, and methods of use
CN110035751A (zh) 一种维利帕尼缓控释药物组合物及其用途